Charles Witherspoon Sells 1,029 Shares of West Pharmaceutical Services, Inc. (NYSE:WST) Stock

West Pharmaceutical Services, Inc. (NYSE:WST) VP Charles Witherspoon sold 1,029 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $300.00, for a total value of $308,700.00. Following the completion of the sale, the vice president now owns 1,478 shares in the company, valued at approximately $443,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

West Pharmaceutical Services Stock Performance

NYSE:WST traded up $5.19 on Wednesday, hitting $304.31. The company’s stock had a trading volume of 195,462 shares, compared to its average volume of 567,375. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03. The stock has a fifty day moving average of $313.88 and a two-hundred day moving average of $348.63. The firm has a market capitalization of $22.07 billion, a P/E ratio of 40.15, a price-to-earnings-growth ratio of 10.68 and a beta of 1.00. West Pharmaceutical Services, Inc. has a one year low of $265.00 and a one year high of $415.73.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The firm had revenue of $702.10 million for the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. West Pharmaceutical Services’s revenue for the quarter was down 6.9% on a year-over-year basis. During the same quarter last year, the business posted $2.11 EPS. Research analysts predict that West Pharmaceutical Services, Inc. will post 6.44 earnings per share for the current year.

Hedge Funds Weigh In On West Pharmaceutical Services

A number of large investors have recently made changes to their positions in the company. Evoke Wealth LLC acquired a new stake in West Pharmaceutical Services during the fourth quarter worth approximately $7,770,000. Sumitomo Mitsui Trust Holdings Inc. grew its position in West Pharmaceutical Services by 1.5% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 191,469 shares of the medical instruments supplier’s stock worth $75,766,000 after buying an additional 2,759 shares in the last quarter. Vanguard Group Inc. grew its position in West Pharmaceutical Services by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 9,002,632 shares of the medical instruments supplier’s stock worth $3,170,007,000 after buying an additional 104,740 shares in the last quarter. Mizuho Markets Americas LLC grew its position in West Pharmaceutical Services by 142.3% during the first quarter. Mizuho Markets Americas LLC now owns 29,628 shares of the medical instruments supplier’s stock worth $11,724,000 after buying an additional 17,399 shares in the last quarter. Finally, Hsbc Holdings PLC grew its position in West Pharmaceutical Services by 39.8% during the fourth quarter. Hsbc Holdings PLC now owns 138,468 shares of the medical instruments supplier’s stock worth $48,750,000 after buying an additional 39,392 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.